Skip to main content
Retour
MSMKF logo

MatsukiyoCocokara & Co.

Qualité des données : 100%
Suracheté
MSMKF
OTC Healthcare Medical - Pharmaceuticals
18,17 €
0,00 € (0,00%)
Cap. Boursière : 7,23B
Fourchette du Jour
18,17 € 20,43 €
Fourchette 52 Semaines
14,09 € 21,22 €
Volume
24
Moyenne 50J / 200J
18,17 € / 19,03 €
Clôture Précédente
18,17 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E 0,1 0,3
P/B 0,0 2,9
ROE % 10,6 3,7
Net Margin % 5,2 3,8
Rev Growth 5Y % 17,5 10,0
D/E 0,0 0,2

Objectif de Cours des Analystes

Aucune couverture d'analyste disponible

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 195,59 €
191,17 € – 199,53 €
1300 B 1
FY2029 185,85 €
181,64 € – 189,59 €
1200 B 1
FY2028 162,15 €
158,48 € – 165,42 €
1200 B 1

Points Clés

Revenue grew 17,50% annually over 5 years — strong growth
ROE of 10,56% — decent returns on equity
Debt/Equity of 0,00 — conservative balance sheet
Generating 67,01B in free cash flow
P/E of 0,13 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 13,68%

Croissance

Revenue Growth (5Y)
17,50%
Revenue (1Y)3,82%
Earnings (1Y)4,45%
FCF Growth (3Y)19,01%

Qualité

Return on Equity
10,56%
ROIC11,77%
Net Margin5,15%
Op. Margin7,73%

Sécurité

Debt / Equity
0,00
Current Ratio2,24
Interest Coverage1282,53

Valorisation

P/E Ratio
0,13
P/B Ratio0,01
EV/EBITDA-1,25
Dividend Yield0,02%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 3,82% Revenue Growth (3Y) 5,64%
Earnings Growth (1Y) 4,45% Earnings Growth (3Y) 16,13%
Revenue Growth (5Y) 17,50% Earnings Growth (5Y) 26,13%
Profitability
Revenue (TTM) 1,06T Net Income (TTM) 54,68B
ROE 10,56% ROA 7,67%
Gross Margin 35,06% Operating Margin 7,73%
Net Margin 5,15% Free Cash Flow (TTM) 67,01B
ROIC 11,77% FCF Growth (3Y) 19,01%
Safety
Debt / Equity 0,00 Current Ratio 2,24
Interest Coverage 1282,53 Dividend Yield 0,02%
Valuation
P/E Ratio 0,13 P/B Ratio 0,01
P/S Ratio 0,01 PEG Ratio 2,32
EV/EBITDA -1,25 Dividend Yield 0,02%
Market Cap 7,23B Enterprise Value -102,31B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1,06T 1,02T 951,25B 729,97B 556,91B
Net Income 54,68B 52,35B 40,55B 34,38B 21,60B
EPS (Diluted) 133,81 125,27 95,99 93,78 70,12
Gross Profit 372,24B 331,80B 329,32B 240,30B 182,10B
Operating Income 82,08B 75,71B 62,28B 41,41B 31,53B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 712,78B 724,75B 688,13B 656,74B 368,92B
Total Liabilities 191,28B 209,57B 205,42B 192,40B 122,46B
Shareholders' Equity 520,80B 514,73B 482,47B 464,32B 246,46B
Total Debt 2,21B 20,66B 21,41B 22,92B 23,70B
Cash & Equivalents 111,75B 117,72B 95,22B 74,52B 38,52B
Current Assets 364,32B 370,80B 329,81B 304,39B 175,70B
Current Liabilities 162,64B 179,43B 153,27B 142,45B 84,89B

Scores de Stratégies

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches

Activité Récente

Entré Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entré Defensive Investing (Benjamin Graham)
Mar 24, 2026